Buscar en
Revista Colombiana de Reumatología
Toda la web
Inicio Revista Colombiana de Reumatología Asociación entre títulos de anticuerpos anticardiolipinas y eventos trombótic...
Información de la revista
Vol. 18. Núm. 2.
Páginas 88-95 (Junio 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 18. Núm. 2.
Páginas 88-95 (Junio 2011)
DOI: 10.1016/S0121-8123(11)70124-4
Acceso a texto completo
Asociación entre títulos de anticuerpos anticardiolipinas y eventos trombóticos
Association between anticardiolipin titles and thrombotic events
Visitas
...
Adriana Lucía Vanegas1,2, James Díaz-Betancur1, Marcos Arango Barrientos1, Germán Andrés Velásquez2, Juan Manuel Toro2, Gloria María Vásquez3,
Autor para correspondencia
glomavas@gmail.com

Correspondencia: Centro de trabajo: Universidad de Antioquia, Medellín, Colombia. Dirección postal: Cra. 53 núm. 61-30. Sede de Investigación Universitaria, Laboratorio 510. Medellín, Colombia.
1 MD, residente de Reumatología, Universidad de Antioquia, Medellín, Colombia
2 MD, internista, Universidad de Antioquia, Medellín, Colombia
3 MD, DSc, jefe sección de Reumatología, Universidad de Antioquia, Medellín, Colombia
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen
Introducción

la trombosis es la manifestación principal del síndrome antifosfolípido (SAF); los marcadores serológicos de esta entidad son los anticuerpos anticardiolipinas (aCL), la anti-ß2 glicoproteína 1 y el anticoagulante lúpico. Aún se discute si los títulos de aCL o la presencia de un “segundo hit” son factores de riesgo para trombosis.

Objetivo

evaluar la asociación entre fenómenos trombóticos vasculares con la presencia y los títulos de aCL; además del papel de otros factores protrombóticos.

Material y método

estudio descriptivo transversal. Se revisaron historias clínicas de pacientes con sospecha clínica de SAF y con al menos una medición de títulos de aCL, se evaluó la presencia o no de eventos trombóticos y de comorbilidades (segundo hit).

Resultados

historias clínicas de 49 pacientes, 33 con un total de 36 eventos trombóticos de los cuales 23 ocurrieron en lechos venosos y 13 en lechos arteriales. Aunque la mayoría de los pacientes con títulos de aCL > 20 GLP o MLP se encontraban en el grupo de trombosis, no se encontró asociación significativa entre la presencia de trombosis y los títulos de aCL; como tampoco entre trombosis y la existencia de otras comorbilidades.

Conclusiones

los hallazgos encontrados permiten sugerir la mayor frecuencia de eventos trombóticos en pacientes con títulos de aCL < 40 en dos mediciones y aportan información sobre las características clínicas de los pacientes con aCL y sospecha de SAF en nuestro medio; sin embargo, no son suficientes para categorizarlos como un factor de riesgo definitivo de trombosis.

Palabras clave:
síndrome antifosfolípido
anticardiolipinas
trombosis
Summary
Background

thrombosis is the main clinical manifestation of the antiphospholipid syndrome (APS); anticardiolipin antibodies (aCL), anti-ß2 glycoprotein-1 antibodies and lupus anticoagulant are the serological markers of the disease. Whether the titles of aCL or the presence of a “second hit” are risk factors for thrombosis is an unresolved issue.

Objective

to evaluate the association between vascular thrombotic events with the presence of aCL. The relationship between thrombosis and the titles of aCL, as well as other prothrombotic factors was also assessed.

Methodology

descriptive cross-sectional study. The clinical charts of patients with possible APS and at least one laboratory measurement of aCL were reviewed. The presence of thrombotic events and the existence of comorbid states (second hit) were also evaluated.

Results

the records of 49 patients were assessed, 33 with a total of 36 thrombotic events, 23 had occurred on veins, and 13 on arteries. Though the majority of the patients that had titles of aCL above of 20 GPL or MPL were located in the group of thrombosis, there was no significant association between the titles of aCL and the presence of thrombosis. Neither significant association was found between thrombosis and the presence of other comorbid states.

Conclusions

these findings allow suggesting the increased frequency of thrombotic events in patients with titers of aCL lower than 40 twice and also add information about the clinical characteristics of patients with aCL and suspected APS in our region; however, they are not enough to categorize them as a definitive risk factor of thrombosis.

Key words:
antiphospholipid syndrome
anticardiolipin
thrombosis
El Texto completo está disponible en PDF
Referencias
[1.]
S. Miyakis, M.D. Lockshin, T. Atsumi, D.W. Branch, R.L. Brey, R. Cervera, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
J Thromb Haemost, 4 (2006), pp. 295-306
[2.]
R. Cervera, J.C. Piette, J. Font, M.A. Khamashta, Y. Shoenfeld, M.T. Camps, et al.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
Arthritis Rheum, 46 (2002), pp. 1019-1027
[3.]
F. Wisloff, E.M. Jacobsen, S. Liestol.
Laboratory diagnosis of the antiphospholipid syndrome.
Thromb Res, 108 (2002), pp. 263-271
[4.]
Anticardiolipin antibodies are an independent risk factor for first ischemic stroke.
The Antiphospholipid Antibodies in Stroke Study (APASS) Group.
Neurology, 43 (1993), pp. 2069-2073
[5.]
S.R. Levine, L. Salowich-Palm, K.L. Sawaya, M. Perry, H.J. Spencer, H.J. Winkler, et al.
IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.
Stroke, 28 (1997), pp. 1660-1665
[6.]
S.R. Levine, R.L. Brey, B.C. Tilley, J.L. Thompson, R.L. Sacco, R.R. Sciacca, et al.
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.
Jama, 291 (2004), pp. 576-584
[7.]
M. Turiel, P. Sarzi-Puttini, R. Peretti, E. Rossi, F. Atzeni, W. Parsons, et al.
Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study.
[8.]
J.S. Ginsberg, P.S. Wells, P. Brill-Edwards, D. Donovan, K. Moffatt, M. Johnston, et al.
Antiphospholipid antibodies and venous thromboembolism.
Blood, 86 (1995), pp. 3685-3691
[9.]
E. Oger, C. Lernyer, M. Dueymes, E. Le Moigne, L. Bressolette, M. Escoffre, et al.
Association between IgM anticardiolipin antibodies and deep venous thrombosis in patients without systemic lupus erythematosus.
Lupus, 6 (1997), pp. 455-461
[10.]
I.A. Naess, S.C. Christiansen, S.C. Cannegieter, F.R. Rosendaal, J. Hammerstroem.
A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study).
J Thromb Haemost, 4 (2006), pp. 44-49
[11.]
R.T. Urbanus, B. Siegerink, M. Roest, F.R. Rosendaal, P.G. de Groot, A. Algra.
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.
Lancet Neurol, 8 (2009), pp. 998-1005
[12.]
M. Hudson, A.L. Herr, J. Rauch, C. Neville, E. Chang, R. Ibrahim, et al.
The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.
J Rheumatol, 30 (2003), pp. 2385-2391
[13.]
W.F. Baker Jr., R.L. Bick, J. Fareed.
Controversies and Unresolved Issues in Antiphospholipid Syndrome Pathogenesis and Management.
Hematol Oncol Clin North Am, 22 (2008), pp. 155-174
[14.]
J.A. Giron-Gonzalez, E. Garcia del Rio, C. Rodriguez, J. Rodriguez-Martorell, A. Serrano.
Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.
J Rheumatol, (2004), pp. 1560-1567
[15.]
F. Vargas, L.F. Pinto.
Síndrome Antifosfolípido: morbilidad y evolución de una cohorte de pacientes del Hospital Pablo Tobón Uribe de Medellín-Colombia.
Revista Colombiana de Reumatología, 13 (2006), pp. 109-119
[16.]
G. Finazzi, V. Brancaccio, M. Moia, N. Ciaverella, M.G. Mazzucconi, P.C. Schinco, et al.
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.
Am J Med, 100 (1996), pp. 530-536
[17.]
I. Marai, Y. Levi, G. Godard, Y. Shoenfeld.
Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population.
Harefuah, 140 (2001), pp. 495-500
[18.]
J. Musial, J. Swadzba, A. Motyl, T. Iwaniec.
Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis.
J Rheumatol, 30 (2003), pp. 723-730
[19.]
S. Sairam, B.A. Baethge, T. McNearney.
Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies.
Clin Rheumatol, 22 (2003), pp. 24-29
[20.]
A. Ruffatti, T. Del Ross, M. Ciprian, M. Nuzzo, M. Rampudda, M.T. Bertero, et al.
Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study.
Ann Rheum Dis, 68 (2009), pp. 397-399
[21.]
N.M. Amin.
Antiphospholipid syndromes in infectious diseases.
Hematol Oncol Clin North Am, 22 (2008), pp. 131-143
[22.]
D. Sene, J.C. Piette, P. Cacoub.
Antiphospholipid antibodies, antiphospholipid syndrome and infections.
Autoimmun Rev, 7 (2008), pp. 272-277
[23.]
A. Afeltra, M. Vadacca, L. Conti, S. Galluzzo, A.P. Mitterhofer, G.M. Ferri, et al.
Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors.
Arthritis Rheum, 53 (2005), pp. 452-459
[24.]
J.D. Torres, H. Cardona, L. Alvarez, W. Cardona-Maya, S.A. Castaneda, F. Quintero-Rivera, et al.
Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population.
Am J Hematol, 81 (2006), pp. 933-937
[25.]
W. Miesbach.
Neurologic symptoms as a feature of the antiphospholipid syndrome.
Semin Thromb Hemost, 34 (2008), pp. 286-289
[26.]
J.F. Tellez-Zenteno, J.M. Remes-Troche, R.O. Negrete-Pulido, L. Davila-Maldonado.
Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases.
Lupus, 10 (2001), pp. 851-856
[27.]
X. Lu, Y. Gu, Y. Wang, S. Chen, S. Ye.
Prognostic factors of lupus myelopathy.
Lupus, 17 (2008), pp. 323-328
[28.]
D.P. D’Cruz, S. Mellor-Pita, B. Joven, G. Sanna, J. Allanson, J. Taylor, et al.
Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies.
J Rheumatol, 31 (2004), pp. 280-285
Copyright © 2011. Asociación Colombiana de Reumatología
Opciones de artículo
Herramientas